<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALLEGRA- fexofenadine hydrochloride tablet, orally disintegrating </strong><br><strong>ALLEGRA- fexofenadine hydrochloride tablet, film coated </strong><br><strong>ALLEGRA- fexofenadine hydrochloride suspension </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ALLEGRA safely and effectively. See full prescribing information for ALLEGRA.<br><br>ALLEGRA (fexofenadine hydrochloride) tablet, orally disintegrating for oral use <br>ALLEGRA (fexofenadine hydrochloride) tablet, film coated for oral use <br>ALLEGRA (fexofenadine hydrochloride) suspension for oral use <br>Initial U.S. Approval: 1996 </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%"><tbody class="Headless">
<tr class="First Toprule">
<td>Dosage and Administration, ALLEGRA ODT (<a href="#S1">2.2</a>)</td>
<td>[7/2007]</td>
</tr>
<tr class="Botrule Last">
<td>Dosage and Administration, ALLEGRA oral suspension(<a href="#S1">2.3</a>)</td>
<td>[10/2006]</td>
</tr>
</tbody></table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ALLEGRA is an H<span class="Sub">1</span>-receptor antagonist indicated for: </p>
<ul>
<li>Relief of symptoms associated with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in patients ≥ 2 years of age (<a href="#S1.1">1.1</a>)</li>
<li>Treatment of uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in patients ≥ 6 months of age. (<a href="http://S1.2">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Rrule" align="center">Patient Population</th>
<th class="Lrule" align="center">ALLEGRA tablets (2.1)</th>
<th class="Lrule" align="center">ALLEGRA ODT (2.2)</th>
<th class="Lrule" align="center">ALLEGRA oral suspension (2.3)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>starting dose in patients with decreased renal function should be the recommended dose indicated above but administered once daily</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>dose not for use in patients with decreased renal function</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>indicated for chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> only</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">Adults and children ≥ 12 years</td>
<td class="Lrule" align="center">60 mg twice daily<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> or 180 mg once daily <a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Lrule" align="center">N/A</td>
<td class="Lrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Children 6 to 11 years</td>
<td class="Lrule" align="center">30 mg twice daily<a href="#footnote-1" class="Sup">*</a> </td>
<td class="Lrule" align="center">30 mg twice daily<a href="#footnote-1" class="Sup">*</a> </td>
<td class="Lrule" align="center">30 mg twice daily<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Children 2 to 5 years</td>
<td class="Lrule" align="center">N/A</td>
<td class="Lrule" align="center">N/A</td>
<td class="Lrule" align="center">30 mg twice daily<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Children 6 months to less than 2 years</td>
<td class="Lrule" align="center">N/A</td>
<td class="Lrule" align="center">N/A</td>
<td class="Lrule" align="center">15 mg twice daily<a href="#footnote-1" class="Sup">*</a><span class="Sup">,</span> <a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
</tbody>
</table>
<ul>
<li><p class="Highlighta">ALLEGRA tablets take with water (<a href="#S2.1">2.1</a>) </p></li>
<li><p class="Highlighta">ALLEGRA ODT: take on an empty stomach: allow to disintegrate on the tongue and swallow with or without water; do not remove from original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until time of administration; do not break or use partial tablets (<a href="#S2.2">2.2</a>) </p></li>
</ul>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div><div><div></div></div></div>
<div>
<div><div></div></div>
<div><div></div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>ALLEGRA tablets: 30 mg, 60 mg, and 180 mg (<a href="#S3">3</a>)</li>
<li>ALLEGRA ODT: 30 mg (<a href="#S3">3</a>)</li>
<li>ALLEGRA oral suspension: 30 mg/5 mL (6 mg/mL) (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fexofenadine and any of the ingredients of ALLEGRA(<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li>ALLEGRA ODT contains phenylalanine, a component of aspartame. Other ALLEGRA products do not contain phenylalanine.</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥ 2%) in subjects age 12 years and older were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>.  In subjects aged 6 to 11 years, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were more frequently reported. In subjects aged 6 months to 5 years, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> were more frequently reported. (<a href="#S6.1">6.1</a>)  Other adverse reactions have been reported. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Antacids: Do not take at the same time as aluminum and magnesium containing antacids (<a href="#S7.2">7.1</a>)</li>
<li>Fruit juice: Take with water; not fruit juice</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul>
<li>Pregnancy: Use only if benefit justifies risk to fetus (<a href="#S8.1">8.1</a>)</li>
<li>Nursing Mothers: Use with caution (<a href="#S8.3">8.3</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">See <a href="#S17">17</a> for PATIENT COUNSELING INFORMATION</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 ALLEGRA tablets</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 ALLEGRA ODT</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 ALLEGRA oral suspension </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Phenylketonurics</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antacids</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Erythromycin and Ketoconazole</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Fruit Juices </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 ALLEGRA tablets</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 ALLEGRA ODT</a></h2>
<h2><a href="#section-14.3" class="toc">16.3 ALLEGRA oral suspension </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> </h2>
<p class="First">ALLEGRA is indicated for the relief of symptoms associated with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in adults and children 2 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<p class="First">ALLEGRA is indicated for treatment of uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in adults and children 6 months of age and older.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 ALLEGRA tablets</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> and Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1.1"></a><p></p>
<h4>Adults and Children 12 Years and Older</h4>
<p class="First"><span class="Italics"></span> The recommended dose of ALLEGRA tablets is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function <span class="Italics">[see </span><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1.2"></a><p></p>
<h4>Children 6 to 11 Years.</h4>
<p class="First"><span class="Italics"></span> The recommended dose of ALLEGRA tablets is 30 mg twice daily with water. A dose of 30 mg once daily is recommended as the starting dose in pediatric patients with decreased renal function <span class="Italics">[see </span><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span><span class="Italics">)].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 ALLEGRA ODT</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> and Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1.1"></a><p></p>
<h4>Children 6 to 11 Years:</h4>
<p class="First"><span class="Italics"></span> ALLEGRA ODT is intended for use only in children 6 to 11 years of age. The recommended dose of ALLEGRA ODT is 30 mg twice daily. A dose of 30 mg once daily is recommended as the starting dose in pediatric patients with decreased renal function <span class="Italics">[see </span><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span><span class="Italics">)]</span>.</p>
<p>ALLEGRA ODT is designed to disintegrate on the tongue, followed by swallowing with or without water. ALLEGRA ODT should be taken on an empty stomach. ALLEGRA ODT is not intended to be chewed.</p>
<p>ALLEGRA ODT should not be removed from the original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until the time of administration.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 ALLEGRA oral suspension </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1.1"></a><p></p>
<h4>Children 2 to 11 Years:</h4>
<p class="First"><span class="Italics"></span> The recommended dose of ALLEGRA oral suspension is 30 mg twice daily. A dose of 30 mg (5 mL) once daily is recommended as the starting dose in pediatric patients with decreased renal function <span class="Italics">[see </span><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span><span class="Italics">)].</span></p>
<p></p>
<p>Shake bottle well, before each use.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<h3>Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2.1"></a><p></p>
<h4>Children 6 Months to 11 Years:</h4>
<p class="First"><span class="Italics"></span> The recommended dose of ALLEGRA oral suspension is 30 mg (5 mL) twice daily for patients 2 to 11 years of age and 15 mg (2.5 mL) twice daily for patients 6 months to less than 2 years of age.  For pediatric patients with decreased renal function, the recommended starting doses of ALLEGRA oral suspension are 30 mg (5 mL) once daily for patients 2 to 11 years of age and 15 mg  (2.5 mL) once daily for patients 6 months to less than 2 years of age <span class="Italics">[see </span><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span><span class="Italics">)].</span></p>
<p>Shake bottle well, before each use.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ALLEGRA tablets are available in 30 mg, 60 mg, and 180 mg strengths. ALLEGRA tablets are coated with a peach colored film coating. Tablets have the following unique shape and identifiers: 30 mg tablets are round, bi-convex and have 03 on one side and a scripted "e" on the other; 60 mg tablets are oval, bi-convex and have 06 on one side and a scripted "e" on the other; and 180 mg tablets are oblong, bi-convex and have 018 on one side and a scripted "e" on the other.</p>
<p>ALLEGRA ODT is available as a 30 mg orally disintegrating tablet and is white, flat-faced, ½-inch round shaped with beveled edges and debossed with a scripted "e" on one side and "311AV" on the other side.</p>
<p>ALLEGRA oral suspension is available as 30 mg/ 5 mL (6 mg/mL).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ALLEGRA tablets, ALLEGRA ODT and ALLEGRA oral suspension are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fexofenadine and any of the ingredients of ALLEGRA. Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> with manifestations such as <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">systemic anaphylaxis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5.1"></a><p></p>
<h2>5.1 Phenylketonurics</h2>
<p class="First">ALLEGRA ODT contains phenylalanine, a component of aspartame. Each 30 mg ALLEGRA ODT contains 5.3 mg phenylalanine. ALLEGRA products other than ALLEGRA ODT do not contain phenylalanine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety data described below reflect exposure to fexofenadine hydrochloride in 5083 patients in trials for <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> and chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>.  In these trials, 3010 patients 12 years of age and older with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> were exposed to fexofenadine hydrochloride at doses of 20 to 240 mg twice daily or 120 to 180 mg once daily.  A total of 646 patients 6 to 11 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> were exposed to fexofenadine hydrochloride at doses of 15 to 60 mg twice daily.  The duration of treatment in these trials was 2 weeks.  A total of 534 patients 6 months to 5 years of age with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> were exposed to fexofenadine hydrochloride at doses of 15 to 30 mg twice daily. The duration of treatment in these trials ranged from 1 day to 2 weeks.  There were 893 patients 12 years of age and older with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> exposed to fexofenadine hydrochloride at doses of 20 to 240 mg twice daily or 180 mg once daily.  The duration of treatment in these trials was 4 weeks.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></h3>
<p class="First">Adults and Adolescents: In placebo-controlled <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> clinical trials in subjects 12 years of age and older, 2439 subjects received fexofenadine hydrochloride capsules at doses of 20 mg to 240 mg twice daily. All adverse reactions that were reported by greater than 1% of subjects who received the recommended daily dose of fexofenadine hydrochloride (60 mg capsules twice daily) are listed in Table 1.</p>
<p>In another placebo-controlled clinical study in the United States, 571 subjects aged 12 years and older received fexofenadine hydrochloride tablets at doses of 120 or 180 mg once daily. Table 1 also lists adverse reactions that were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at doses of 180 mg once daily.</p>
<p>The incidence of adverse reactions, including <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, was not dose-related and was similar across subgroups defined by age, gender, and race.</p>
<table width="60%">
<caption><span>Table 1 Adverse reactions in subjects aged 12 years and older reported in placebo-controlled <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> clinical trials in the United States</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First"><td class="Bold" align="center" colspan="3"><span class="Bold">Twice-daily dosing with fexofenadine capsules at rates of greater than 1%</span></td></tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Adverse reaction</span></td>
<td align="center">
<span class="Bold">Fexofenadine 60 mg</span><br><span class="Bold">Twice Daily</span><br>
</td>
<td align="center">
<span class="Bold">Placebo</span><br><span class="Bold">Twice Daily</span><br>
</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center"><span class="Bold">(n=680)</span></td>
<td align="center"><span class="Bold">(n=674)</span></td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></td>
<td align="center">1.5%</td>
<td align="center">0.3%</td>
</tr>
<tr><td class="Bold" align="center" colspan="3"><span class="Bold">Once-daily dosing with fexofenadine hydrochloride tablets at rates of greater than 2%</span></td></tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Adverse reaction</span></td>
<td align="center">
<span class="Bold">Fexofenadine 180 mg</span><br><span class="Bold">Once Daily</span><br>
</td>
<td align="center">
<span class="Bold">Placebo</span><br>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">(n=283)</span></td>
<td align="center"><span class="Bold">(n=293)</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">10.3%</td>
<td align="center">7.2%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">2.5%</td>
<td align="center">1.4%</td>
</tr>
</tbody>
</table>
<p>The frequency and magnitude of laboratory abnormalities were similar in fexofenadine hydrochloride- and placebo-treated subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First">Pediatrics: Table 2 lists adverse reactions in subjects aged 6 years to 11 years of age which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at a dose of 30 mg twice daily in placebo-controlled <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> studies in the United States and Canada.</p>
<table width="60%">
<caption><span>Table 2 Adverse reactions reported in placebo-controlled <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> studies in pediatric subjects aged 6 years to 11 years in the United States and Canada at rates of greater than 2%</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left"><span class="Bold">Adverse reaction</span></th>
<th align="center">
<span class="Bold">Fexofenadine 30 mg</span><br>Twice Daily<br>(n=209)</th>
<th align="center">
<span class="Bold">Placebo</span><span class="Italics"><br></span><span class="Bold">(n=229)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="center">3.8%</td>
<td align="center">1.3%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td align="center">2.9%</td>
<td align="center">0.9%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">2.4%</td>
<td align="center">0.9%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></td>
<td align="center">2.4%</td>
<td align="center">0.0%</td>
</tr>
</tbody>
</table>
<p>Table 3 lists adverse reactions in subjects 6 months to 5 years of age which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride in 3 open single- and multiple-dose pharmacokinetic studies and 3 placebo-controlled safety studies with fexofenadine hydrochloride capsule content (484 subjects) and suspension (50 subjects) at doses of 15 mg (108 subjects) and 30 mg (426 subjects) given twice a day.</p>
<table width="100%">
<caption><span>Table 3 Adverse reactions reported in placebo-controlled studies in pediatric subjects with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> aged 6 months to 5 years of age at rates greater than 2%</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="left"><span class="Bold">Adverse reaction</span></th>
<th align="center">
<span class="Bold">Fexofenadine 15 mg</span><span class="Bold">Twice Daily </span>
</th>
<th align="center">
<span class="Bold">Fexofenadine 30 mg</span><span class="Bold">Twice Daily</span>
</th>
<th align="center">
<span class="Bold">Fexofenadine Total</span><br><span class="Bold">Twice Daily </span>
</th>
<th align="center"><span class="Bold">Placebo</span></th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center"><span class="Bold">(n=108)</span></th>
<th align="center"><span class="Bold">(n=426)</span></th>
<th align="center"><span class="Bold">(n=534)</span></th>
<th align="center"><span class="Bold">(n=430)</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">12.0%</td>
<td align="center">4.2%</td>
<td align="center">5.8%</td>
<td align="center">8.6%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3.7%</td>
<td align="center">2.8%</td>
<td align="center">3.0%</td>
<td align="center">2.6%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">2.8%</td>
<td align="center">0.9%</td>
<td align="center">1.3%</td>
<td align="center">0.2%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td align="center">0.9%</td>
<td align="center">2.1%</td>
<td align="center">1.9%</td>
<td align="center">0.9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3>Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h3>
<p class="First">Adverse reactions reported by subjects 12 years of age and older in placebo-controlled chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> studies were similar to those reported in placebo-controlled <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> studies. </p>
<p>In placebo-controlled chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> clinical trials, 726 subjects 12 years of age and older received fexofenadine hydrochloride tablets at doses of 20 to 240 mg twice daily. Table 4 lists adverse reactions in subjects aged 12 years and older which were reported by greater than 2% of subjects treated with fexofenadine hydrochloride 60 mg tablets twice daily in controlled clinical studies in the United States and Canada.</p>
<p>In a placebo-controlled clinical study in the United States, 167 subjects aged 12 years and older received fexofenadine hydrochloride 180 mg tablets. Table 4 also lists adverse reactions that were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at doses of 180 mg once daily.</p>
<table width="75%">
<caption><span>Table 4 Adverse reactions reported in subjects 12 years of age and older in placebo-controlled chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> studies</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<tbody class="Headless">
<tr class="First"><td class="Bold" align="center" colspan="3"><span class="Bold">Twice-daily dosing with fexofenadine hydrochloride in studies in the United States and Canada at rates of greater than 2%</span></td></tr>
<tr class="Botrule">
<td align="left"><span class="Bold">Adverse reaction</span></td>
<td align="center"><span class="Bold">Fexofenadine 60 mg<br>Twice Daily<br>(n=191)</span></td>
<td align="center"><span class="Bold">Placebo<br>(n=183)</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">2.1%</td>
<td align="center">1.1%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center">2.1%</td>
<td align="center">1.1%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></td>
<td align="center">2.1%</td>
<td align="center">0.6%</td>
</tr>
<tr>
<td align="left">Pan in extremity</td>
<td align="center">2.1%</td>
<td align="center">0.0%</td>
</tr>
<tr><td class="Bold" align="center" colspan="3"><span class="Bold">Once-daily dosing with fexofenadine hydrochloride in a study in the United States at rates of greater than 2%</span></td></tr>
<tr class="Botrule">
<td align="left" valign="middle"><span class="Bold">Adverse reaction</span></td>
<td align="center">
<span class="Bold">Fexofenadine 180 mg</span><br><span class="Bold">Once Daily</span><br><span class="Bold">(n=167) </span>
</td>
<td align="center" valign="middle">
<span class="Bold">Placebo</span><span class="Bold">(n=92)</span>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Frequency</span></td>
<td align="center"><span class="Bold">Frequency</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">4.8%</td>
<td align="center">3.3%</td>
</tr>
</tbody>
</table>
<p>The safety of fexofenadine hydrochloride in the treatment of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in pediatric patients 6 months to 11 years of age is based on the safety profile of fexofenadine hydrochloride in adults and pediatric patients at doses equal to or higher than the recommended dose <span class="Italics">[see </span><span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4</a></span><span class="Italics">)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to the adverse reactions reported during clinical studies and listed above, the following adverse events have been identified during post-approval use of ALLEGRA.  Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Events that have been reported rarely during postmarketing experience include: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span> or <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Antacids</h2>
<p class="First">Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®) decreased fexofenadine AUC by 41% and C<span class="Sub">max</span> by 43%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Erythromycin and Ketoconazole</h2>
<p class="First">Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism. However, co–administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In 2 separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n=24, each study). No differences in adverse events or QT<span class="Sub">c</span> interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole. The findings of these studies are summarized in the following table</p>
<table width="60%">
<caption><span>Table 5 Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours in healthy adult subjects (n=24)</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="34%">
<thead><tr class="First Last">
<th align="left"><span class="Italics">Concomitant Drug</span></th>
<th align="center">
<span class="Italics">C<span class="Sub">maxSS</span></span><br><span class="Italics">(Peak plasma concentration)</span>
</th>
<th align="center">
<span class="Italics">AUC<span class="Sub">ss(0–12h)</span></span><br><span class="Italics">(Extent of systemic exposure)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Erythromycin<br>(500 mg every 8 hrs)</td>
<td align="center">+82%</td>
<td align="center">+109%</td>
</tr>
<tr><td align="center" colspan="3">  </td></tr>
<tr class="Last">
<td align="left">Ketoconazole<br>(400 mg once daily)</td>
<td align="center">+135%</td>
<td align="center">+164%</td>
</tr>
</tbody>
</table>
<p>The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials.</p>
<p>The mechanism of these interactions has been evaluated in <span class="Italics">in vitro, in situ</span>, and <span class="Italics">in vivo</span> animal models. These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. <span class="Italics">In vivo</span> animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 Fruit Juices </h2>
<p class="First">Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine. This is based on the results from 3 clinical studies using histamine induced skin <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water. Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice. The clinical significance of these observations is unknown. In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%. Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA tablets should be taken with water <span class="Italics">[see </span><span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span><span class="Italics"> and </span><span class="Italics"><span class="Italics"><a href="#S2">Dosage and Administration (2.2</a></span></span><span class="Italics">)].</span></p>
<p>ALLEGRA ODT can be taken with or without water.<span class="Italics">(see </span><span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span><span class="Italics"></span><span class="Italics"> and </span><span class="Italics"><a href="#S2">Dosage and Administration (2.1</a></span><span class="Italics">)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First">Teratogenic Effects: Pregnancy Category C. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats or rabbits at oral doses of terfenadine up to 300 mg/kg (which led to fexofenadine exposures that were approximately 4 and 30 times, respectively, the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).</p>
<p>In mice, no adverse effects and no teratogenic effects during gestation were observed with fexofenadine hydrochloride at oral doses up to 3730 mg/kg (which led to fexofenadine exposures that were approximately 15 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).</p>
<p>There are no adequate and well controlled studies in pregnant women. Fexofenadine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<h3></h3>
<p class="First">Nonteratogenic Effects: Dose-related decreases in pup <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and survival were observed in rats exposed to an oral dose of 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if fexofenadine is excreted in human milk. There are no adequate and well-controlled studies in women during lactation. Because many drugs are excreted in human milk, caution should be exercised when fexofenadine hydrochloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The recommended doses of fexofenadine hydrochloride in pediatric patients 6 months to 11 years of age are based on cross-study comparison of the pharmacokinetics of fexofenadine in adults and pediatric subjects and on the safety profile of fexofenadine hydrochloride in both adult and pediatric subjects at doses equal to or higher than the recommended doses.The safety and effectiveness of fexofenadine hydrochloride in pediatric patients under 6 months of age have not been established.</p>
<p>The safety of fexofenadine hydrochloride is based on the administration of ALLEGRA tablets at a dose of 30 mg twice daily demonstrated in 438 pediatric subjects 6 years to 11 years of age in 2 placebo-controlled 2-week <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> trials. The safety of fexofenadine hydrochloride at doses of 15mg and 30 mg given once and twice a day has been demonstrated in 969 pediatric subjects (6 months to 5 years of age) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> in 3 pharmacokinetic studies and 3 safety studies. The safety of fexofenadine hydrochloride for the treatment of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in subjects 6 months to 11 years of age is based on cross-study comparison of the pharmacokinetics of ALLEGRA in adult and pediatric subjects and on the safety profile of fexofenadine in both adult and pediatric subjects at doses equal to or higher than the recommended dose.</p>
<p>The effectiveness of fexofenadine hydrochloride for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in subjects 6 to 11 years of age was demonstrated in 1 trial (n=411) in which ALLEGRA tablets 30 mg twice daily significantly reduced total symptom scores compared to placebo, along with extrapolation of demonstrated efficacy in subjects aged 12 years and above, and the pharmacokinetic comparisons in adults and children. The effectiveness of fexofenadine hydrochloride 30 mg twice daily for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in patients 2 to 5 years of age is based on the pharmacokinetic comparisons in adult and pediatric subjects and an extrapolation of the demonstrated efficacy of fexofenadine hydrochloride in adult subjects with this condition and the likelihood that the disease course, pathophysiology, and the drug's effect are substantially similar in pediatric patients to those in adult patients. The effectiveness of fexofenadine hydrochloride for the treatment of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in patients 6 months to 11 years of age is based on the pharmacokinetic comparisons in adults and children and an extrapolation of the demonstrated efficacy of ALLEGRA in adults with this condition and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar in children to that of adult patients. Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of ALLEGRA tablets and capsules did not include sufficient numbers of subjects aged 65 years and over to determine whether this population responds differently from younger subjects. Other reported clinical experience has not identified differences in responses between the geriatric and younger subjects. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span></span><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function (mild, moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>). For pediatric patients with decreased renal function (mild, moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age. <span class="Italics"></span><span class="Italics">[See </span><span class="Italics"><a href="#S12.3">Dosage and Administration (2.2,</a><a href="#S2.3">2.3</a> ) and <a href="#S2.2">Clinical Pharmacology (12.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of fexofenadine hydrochloride in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not differ substantially from that observed in healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> have been reported with fexofenadine hydrochloride <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Single doses of fexofenadine hydrochloride up to 800 mg (6 healthy subjects at this dose level), and doses up to 690 mg twice daily for 1 month (3 healthy subjects at this dose level) or 240 mg once daily for 1 year (234 healthy subjects at this dose level) were administered without the development of clinically significant adverse events as compared to placebo.</p>
<p>In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Following administration of terfenadine, hemodialysis did not effectively remove fexofenadine, the major active metabolite of terfenadine, from blood (up to 1.7% removed).</p>
<p>No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurred at oral doses of fexofenadine hydrochloride up to 5000 mg/kg in mice (110 times the maximum recommended daily oral dose in adults and children based on mg/m<span class="Sup">2</span>) and up to 5000 mg/kg in rats (230 times the maximum recommended daily oral dose in adults and 210 times the maximum recommended daily oral dose in children based on mg/m<span class="Sup">2</span>). Additionally, no clinical signs of toxicity or gross pathological findings were observed. In dogs, no evidence of toxicity was observed at oral doses up to 2000 mg/kg (300 times the maximum recommended daily oral dose in adults and 280 times the maximum recommended daily oral dose in children based on mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Fexofenadine hydrochloride, the active ingredient of ALLEGRA tablets, ALLEGRA ODT and ALLEGRA oral suspension, is a histamine H<span class="Sub">1</span>-receptor antagonist with the chemical name (±)-4-[1 hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid hydrochloride. It has the following chemical structure</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-01.jpg"></div>
<p>The molecular weight is 538.13 and the empirical formula is C<span class="Sub">32</span>H<span class="Sub">39</span>NO<span class="Sub">4</span>•HCl.</p>
<p>Fexofenadine hydrochloride is a white to off-white crystalline powder. It is freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane. Fexofenadine hydrochloride is a racemate and exists as a zwitterion in aqueous media at physiological pH.</p>
<p>ALLEGRA is formulated as a tablet for oral administration. Each tablet contains 30, 60, or 180 mg fexofenadine hydrochloride (depending on the dosage strength) and the following excipients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The aqueous tablet film coating is made from hypromellose, iron oxide blends, polyethylene glycol, povidone, silicone dioxide, and titanium dioxide.</p>
<p>ALLEGRA ODT is formulated for disintegration in the mouth immediately following administration. Each orally disintegrating tablet contains 30 mg fexofenadine hydrochloride and the following excipients: citric acid anhydrous, crospovidone, magnesium stearate, mannitol, methacrylate copolymer, microcrystalline cellulose, povidone K-30, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, sodium starch glycolate, aspartame, natural and artificial orange flavor, artificial cream flavor, and alcohol anhydrous; the alcohol is predominantly removed during the manufacturing process.</p>
<p>ALLEGRA oral suspension, a white uniform suspension, contains 6 mg fexofenadine hydrochloride per mL and the following excipients: propylene glycol, edetate disodium, propylparaben, butylparaben, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H<span class="Sub">1</span>-receptor antagonist activity. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Fexofenadine hydrochloride inhibited antigen-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in sensitized guinea pigs and histamine release from peritoneal mast cells in rats. The clinical significance of these findings is unknown. In laboratory animals, no anticholinergic or alpha<span class="Sub">1</span>-adrenergic blocking effects were observed. Moreover, no sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Wheal and Flare.</span> Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by 1 hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours. There was no evidence of tolerance to these effects after 28 days of dosing. The clinical significance of these observations is unknown. </p>
<p>Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 or 60 mg, antihistamine effect was observed at 1 hour and reached a maximum by 3 hours. Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 and 60 mg dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First">No statistically significant increase in mean QT<span class="Sub">c</span> interval compared to placebo was observed in 714 adult subjects with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> given fexofenadine hydrochloride capsules in doses of 60 to 240 mg twice daily for 2 weeks. Pediatric subjects from 2 placebo-controlled trials (n=855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QT<span class="Sub">c</span>. In addition, no statistically significant increase in mean QT<span class="Sub">c</span> interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for 1 year. In subjects with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>, there were no clinically relevant differences for any ECG intervals, including QT<span class="Sub">c</span>, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of fexofenadine hydrochloride in subjects with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> and subjects with <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span> were similar to those in healthy subjects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<h3>Absorption:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Italics">ALLEGRA tablets:</span> Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose. After administration of a single 60 mg capsule to healthy adult subjects, the mean maximum plasma concentration (Cmax) was 131 ng/mL. Following single dose oral administrations of either the 60 and 180 mg tablet to healthy adult male subjects, mean Cmax were 142 and 494 ng/mL, respectively. The tablet formulations are bioequivalent to the capsule when administered at equal doses. Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily). The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults. Co-administration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21 and 20% respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Italics">ALLEGRA ODT:</span> Fexofenadine hydrochloride was absorbed following single-dose oral administration of ALLEGRA ODT 30 mg to healthy adult subjects with a mean time to maximum plasma concentration occurring at approximately 2.0 hours post-dose.  After single-dose administration of ALLEGRA 30 mg ODT to healthy adult subjects, the mean maximum plasma concentration (Cmax) was 88.0 ng/mL. ALLEGRA ODT 30 mg tablets are bioequivalent to the 30 mg ALLEGRA tablets. The administration of ALLEGRA ODT 30 mg with a high-fat meal decreased the AUC and Cmax by approximately 40% and 60% respectively and a 2-hour delay in the time to peak exposure (Tmax) was observed. ALLEGRA ODT should be taken on an empty stomach. The bioavailability of ALLEGRA ODT was comparable whether given with or without water <span class="Italics">[see </span><span class="Italics"><a href="#S2">Dosage and Administration (2.2</a></span><span class="Italics">)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.3"></a><p></p>
<p class="First"><span class="Italics">ALLEGRA oral suspension:</span> A dose of 5 mL of ALLEGRA oral suspension containing 30 mg of fexofenadine hydrochloride is bioequivalent to a 30 mg dose of ALLEGRA tablets. Following oral administration of a 30 mg dose of ALLEGRA oral suspension to healthy adult subjects, the mean Cmax was 118 ng/mL and occurred at approximately 1 hour. The administration of 30 mg ALLEGRA oral suspension with a high fat meal decreased the AUC and the mean Cmax by approximately 30 and 47%, respectively in healthy adult subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<h3>Distribution:</h3>
<p class="First">Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α<span class="Sub">1</span>-acid glycoprotein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<h3>Metabolism:</h3>
<p class="First">Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<h3>Elimination:</h3>
<p class="First">The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.</p>
<p>Human <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance studies documented a recovery of approximately 80% and 11% of the [<span class="Sup">14</span>C] fexofenadine hydrochloride dose in the feces and urine, respectively. Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<h3>Special Populations:</h3>
<p class="First">Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<h4><span class="Italics">Renally Impaired:</span></h4>
<p class="First">In subjects with mild to moderate (creatinine clearance 41–80 mL/min) and severe (creatinine clearance 11–40 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects. Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects. Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function. For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.<span class="Italics">[see </span><span class="Italics"><span class="Italics"><span class="Italics"><a href="#S2">Dosage and Administration (2.2,</a></span></span></span><span class="Italics"><span class="Italics"><a href="#S2.3">2.3</a></span>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<h4><span class="Italics">Hepatically Impaired:</span></h4>
<p class="First">The pharmacokinetics of fexofenadine hydrochloride in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not differ substantially from that observed in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<h4><span class="Italics">Geriatric Subjects:</span></h4>
<p class="First">In older subjects (≥65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (&lt;65 years old). Mean fexofenadine elimination half-lives were similar to those observed in younger subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<h4>Pediatric Subjects:</h4>
<p class="First">A population pharmacokinetic analysis was performed with data from 77 pediatric subjects (6 months to 12 years of age) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> and 136 adult subjects.  The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n=14) and 2 to 5 years of age (n=21), respectively, compared to adult subjects. </p>
<p>Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<h4>Effect of Gender.</h4>
<p class="First">Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The carcinogenic potential of fexofenadine was assessed using terfenadine studies with adequate fexofenadine exposure (based on plasma area-under-the-concentration vs. time [AUC] values). No evidence of carcinogenicity was observed in an 18-month study in mice and in a 24-month study in rats at oral doses up to 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 and 5 times the exposure at the maximum recommended daily oral dose of fexofenadine hydrochloride in adults [180 mg] and children [60 mg] respectively).</p>
<p>In <span class="Italics"> in vitro</span> (Bacterial Reverse Mutation, CHO/HGPRT Forward Mutation, and Rat Lymphocyte Chromosomal Aberration assays) and <span class="Italics">in vivo</span> (Mouse Bone Marrow Micronucleus assay) tests, fexofenadine hydrochloride revealed no evidence of mutagenicity.</p>
<p>In rat fertility studies, dose-related reductions in implants and increases in postimplantation losses were observed at an oral dose of 150 mg/kg of terfenadine (which led to fexofenadine exposures that were approximately 3 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs). In mice, fexofenadine hydrochloride produced no effect on male or female fertility at average oral doses up to 4438 mg/kg (which led to fexofenadine exposures that were approximately 13 times the exposure at the maximum recommended human daily oral dose of 180 mg of fexofenadine hydrochloride based on comparison of AUCs).</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">In dogs (30 mg/kg/orally twice daily for 5 days) and rabbits (10 mg/kg, intravenously over 1 hour), fexofenadine hydrochloride did not prolong QT<span class="Sub">c</span>. In dogs, the plasma fexofenadine concentration was approximately 9 times the therapeutic plasma concentrations in adults receiving the maximum recommended human daily oral dose of 180 mg. In rabbits, the plasma fexofenadine concentration was approximately 20 times the therapeutic plasma concentration in adults receiving the maximum recommended human daily oral dose of 180 mg. No effect was observed on calcium channel current, delayed K<span class="Sup">+</span> channel current, or action potential duration in guinea pig myocytes, or on the delayed rectifier K<span class="Sup">+</span> channel cloned from human heart at concentrations up to 1 x 10<span class="Sup">-5</span> M of fexofenadine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Adults:</span> In three 2-week, multicenter, randomized, double-blind, placebo-controlled trials in subjects 12 to 68 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> (n=1634), fexofenadine hydrochloride 60 mg twice daily significantly reduced total symptom scores (the sum of the individual scores for <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose/palate/throat, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>/watery/<span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>) compared to placebo. Statistically significant reductions in symptom scores were observed following the first 60 mg dose, with the effect maintained throughout the 12-hour interval. In these studies, there was no additional reduction in total symptom scores with higher doses of fexofenadine hydrochloride up to 240 mg twice daily.</p>
<p>In one 2-week, multicenter, randomized, double-blind clinical trial in subjects 12 to 65 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> (n=863), fexofenadine hydrochloride 180 mg once daily significantly reduced total symptom scores (the sum of the individual scores for <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose/palate/throat, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>/watery/<span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>) compared to placebo. Although the number of subjects in some of the subgroups was small, there were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, and race. Onset of action for reduction in total symptom scores, excluding <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, was observed at 60 minutes compared to placebo following a single 60 mg fexofenadine hydrochloride dose administered to subjects with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> who were exposed to ragweed pollen in an environmental exposure unit. In 1 clinical trial conducted with ALLEGRA 60 mg capsules, and in 1 clinical trial conducted with ALLEGRA-D 12 Hour extended release tablets, onset of action was seen within 1 to 3 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Pediatrics:</span> Two 2-week, multicenter, randomized, placebo-controlled, double-blind trials in 877 pediatric subjects 6 to 11 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> were conducted at doses of 15, 30, and 60 mg (tablets) twice daily. In 1 of these 2 studies, conducted in 411 pediatric subjects, all 3 doses of fexofenadine hydrochloride significantly reduced total symptom scores (the sum of the individual scores for <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose/palate/throat, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>/watery/<span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>) compared to placebo, however, a dose-response relationship was not seen. The 60 mg twice daily dose did not provide any additional benefit over the 30 mg twice daily dose in pediatric subjects 6 to 11 years of age.</p>
<p>Administration of a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.<span class="Italics">[See  </span><span class="Italics"><span class="Italics"><a href="#CLINICAL">Clinical Pharmacology (12.3</a></span>).]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<p class="First">Two 4-week, multicenter, randomized, double-blind, placebo-controlled clinical trials compared four different doses of fexofenadine hydrochloride tablet (20, 60, 120, and 240 mg twice daily) to placebo in subjects aged 12 to 70 years with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> (n=726). Efficacy was demonstrated by a significant reduction in mean <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> scores (MPS), mean number of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> (MNW), and mean total symptom scores (MTSS, the sum of the MPS and MNW score). Although all 4 doses were significantly superior to placebo, symptom reduction was greater and efficacy was maintained over the entire 4-week treatment period with fexofenadine hydrochloride doses of ≥60 mg twice daily. However, no additional benefit of the 120 or 240 mg fexofenadine hydrochloride twice daily dose was seen over the 60 mg twice daily dose in reducing symptom scores. There were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, weight, and race.</p>
<p>In one 4-week, multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects 12 years of age and older with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> (n=259), fexofenadine hydrochloride 180 mg once daily significantly reduced the mean number of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> (MNW), the mean <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> score (MPS), and the mean total symptom score (MTSS, the sum of the MPS and MNW scores). Similar reductions were observed for mean number of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> and mean <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> score at the end of the 24-hour dosing interval. Symptom reduction was greater with fexofenadine hydrochloride180 mg than with placebo. Improvement was demonstrated within 1 day of treatment with fexofenadine hydrochloride 180 mg and was maintained over the entire 4-week treatment period. There were no significant differences in the effect of fexofenadine hydrochloride across subgroups of subjects defined by gender, age, and race.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2>16.1 ALLEGRA tablets</h2>
<p class="First">ALLEGRA 30 mg tablets are available in: high-density polyethylene (HDPE) bottles of 100 (NDC 0088-1106-47) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal and HDPE bottles of 500 (NDC 0088-1106-55) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal.</p>
<p>ALLEGRA 60 mg tablets are available in: HDPE bottles of 100 (NDC 0088-1107-47) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal; HDPE bottles of 500 (NDC 0088-1107-55) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal; and aluminum foil-backed clear <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 (NDC 0088-1107-49).</p>
<p>ALLEGRA 180 mg tablets are available in: HDPE bottles of 100 (NDC 0088-1109-47) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal and HDPE bottles of 500 (NDC 0088-1109-55) with a polypropylene screw cap containing a pulp/wax liner with heat-sealed foil inner seal.</p>
<p>ALLEGRA tablets are coated with a peach colored film coating. Tablets have the following unique shape and identifiers: 30 mg tablets are round, bi-convex and have 03 on one side and a scripted "e" on the other; 60 mg tablets are oval, bi-convex and have 06 on one side and a scripted "e" on the other; and 180 mg tablets are oblong, bi-convex and have 018 on one side and a scripted "e" on the other.</p>
<p>Store ALLEGRA tablets at controlled room temperature 20–25°C (68–77°F). (See USP Controlled Room Temperature). Foil-backed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs containing ALLEGRA tablets should be protected from excessive moisture.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<h2>16.2 ALLEGRA ODT</h2>
<p class="First">ALLEGRA ODT 30 mg orally disintegrating tablets are available in aluminum-foil <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 60 (NDC 0088-1113-30).</p>
<p>Each ALLEGRA ODT is white, flat-faced, ½-inch round shaped with beveled edges and debossed with a scripted "e" on one side and "311AV" on the other side.</p>
<p>Store ALLEGRA ODT at controlled room temperature 20–25°C (68–77°F). (See USP Controlled Room Temperature). Foil-backed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs containing ALLEGRA ODT should be protected from moisture. ALLEGRA ODT should not be removed from the original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until the time of administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<h2>16.3 ALLEGRA oral suspension </h2>
<p class="First">ALLEGRA oral suspension (fexofenadine hydrochloride, 30 mg/5 mL (6 mg/mL)) is available in an amber PET bottle containing 300 mL (NDC 0088-1097-20) of suspension.</p>
<p>Store ALLEGRA oral suspension at controlled room temperature 20–25°C (68–77°F). (See USP Controlled Room Temperature.)</p>
<p>Shake bottle well, before each use.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Provide the following information to patients and parents/caregivers of pediatric patients taking ALLEGRA tablets, ALLEGRA ODT or ALLEGRA oral suspension:</p>
<ul><li><p class="First">ALLEGRA tablets,  ALLEGRA ODT or ALLEGRA oral suspension are prescribed for the relief of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> or for the relief of symptoms of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>). Instruct patients to take ALLEGRA only as prescribed. <span class="Bold">Do not exceed the recommended dose.</span>If any untoward effects occur while taking ALLEGRA, discontinue use and consult a doctor.</p></li></ul>
<ul><li><p class="First">Patients who are hypersensitive to any of the ingredients should not use these products.</p></li></ul>
<ul><li><p class="First">Patients who are pregnant or nursing should use these products only if the potential benefit justifies the potential risk to the fetus or nursing infant.</p></li></ul>
<ul><li><p class="First">Advise patients and parents/caregivers of pediatric patients to store the medication in a tightly closed container in a cool, dry place, away from small children.</p></li></ul>
<ul><li><p class="First">Advise patients and parents/caregivers not to take ALLEGRA with fruit juices.</p></li></ul>
<p>For ALLEGRA tablets: Advise patients to take the ALLEGRA tablets with water.</p>
<p>For ALLEGRA ODT: Advise patients to take their dose on an empty stomach. Allow ALLEGRA ODT to disintegrate on the tongue before swallowing, with or without water. ALLEGRA ODT is not intended to be chewed. Store ALLEGRA ODT in its original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package. Do not remove ALLEGRA ODT from the original <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until the time of administration.</p>
<p><span class="Italics">Phenylketonurics:</span>  ALLEGRA ODT contains phenylalanine, a component of aspartame. Each 30-mg ALLEGRA ODT contains 5.3 mg phenylalanine. ALLEGRA products other than ALLEGRA ODT do not contain phenylalanine.</p>
<p>For ALLEGRA oral suspension: Advise patients and parents/caregivers of pediatric patients to shake the ALLEGRA oral suspension bottle well, before each use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First">sanofi-aventis U.S. LLC</p>
<p>Bridgewater, NJ 08807</p>
<p>ALLEGRA ODT manufactured for:</p>
<p>sanofi-aventis U.S. LLC</p>
<p>Bridgewater, NJ 08807</p>
<p>©2007 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton</span></p>
<p>NDC 0088-1113-30</p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">allegra</span><span class="Sup">®</span><br>fexofenadine HCl</p>
<p><span class="Bold">ODT Orally Disintegrating Tablets, 30 mg</span></p>
<p><span class="Bold">Ten </span> 6 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span></p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 mg Bottle Label</span></p>
<p>NDC 0088-1106-47</p>
<p><span class="Bold">allegra</span><span class="Sup">®</span><br><span class="Italics">fexofenadine hydrochloride</span><br><span class="Bold">Tablets</span></p>
<p><span class="Bold">30</span>mg</p>
<p><span class="Bold">100 </span> Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 mg Bottle Label</span></p>
<p>NDC 0088-1107-47</p>
<p><span class="Bold">allegra</span><span class="Sup">®</span><br><span class="Italics">fexofenadine hydrochloride</span><br><span class="Bold">Tablets</span></p>
<p><span class="Bold">60</span>mg</p>
<p><span class="Bold">100 </span> Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 180 mg Bottle Label</span></p>
<p>NDC 0088-1109-47</p>
<p><span class="Bold">allegra</span><span class="Sup">®</span><br><span class="Italics">fexofenadine<br>hydrochloride</span><br><span class="Bold">Tablets</span></p>
<p><span class="Bold">180</span>mg</p>
<p><span class="Bold">100 </span> Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 300 mL Bottle Label</span></p>
<p>NDC 0088-1097-20</p>
<p><span class="Bold">allegra</span><span class="Sup">®</span><br>fexofenadine HCl<br>Oral Suspension, 30mg/5mL (6mg/mL)</p>
<p>One 300mL Bottle</p>
<p><span class="Bold">sanofi aventis</span></p>
<p><span class="Bold">SHAKE WELL BEFORE USING</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>Each mL of ALLEGRA<span class="Sup">®</span> Oral Suspension contains 6mg<br>of fexofenadine hydrochloride</p>
<p><span class="Bold">Dosage and Administration: </span>See package insert.</p>
<p><span class="Bold">WARNING: </span>Keep out of reach of children.</p>
<p><span class="Bold">Pharmacist: </span>Dispense in light-resistant, tight<br>container with child-resistant closure.</p>
<p><span class="Bold">Store at controlled room temperature 20–25°C<br>(68–77°F). [See USP Controlled Room<br>Temperature].</span></p>
<p><span class="Bold">sanofi-aventis U.S. LLC</span></p>
<p>Bridgewater, NJ 08807<br>©2008<br>50087397</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 300 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c25b695-bbed-4ad1-aa47-de47091bc808&amp;name=allegra-odt-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALLEGRA 		
					</strong><br><span class="contentTableReg">fexofenadine hydrochloride tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-1113</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fexofenadine hydrochloride</strong> (fexofenadine) </td>
<td class="formItem">fexofenadine hydrochloride</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>aspartame</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (round with beveled edges) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">e;311AV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0088-1113-30</td>
<td class="formItem">60  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021909</td>
<td class="formItem">07/26/2007</td>
<td class="formItem">06/30/2013</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALLEGRA 		
					</strong><br><span class="contentTableReg">fexofenadine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-1106</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fexofenadine hydrochloride</strong> (fexofenadine) </td>
<td class="formItem">fexofenadine hydrochloride</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">03;E</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0088-1106-47</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0088-1106-55</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020872</td>
<td class="formItem">02/25/2000</td>
<td class="formItem">09/19/2008</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALLEGRA 		
					</strong><br><span class="contentTableReg">fexofenadine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-1107</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fexofenadine hydrochloride</strong> (fexofenadine) </td>
<td class="formItem">fexofenadine hydrochloride</td>
<td class="formItem">60 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">06;E</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0088-1107-47</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0088-1107-55</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0088-1107-49</td>
<td class="formItem">100  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020872</td>
<td class="formItem">02/25/2000</td>
<td class="formItem">08/31/2012</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALLEGRA 		
					</strong><br><span class="contentTableReg">fexofenadine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-1109</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fexofenadine hydrochloride</strong> (fexofenadine) </td>
<td class="formItem">fexofenadine hydrochloride</td>
<td class="formItem">180 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose acetate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">018;E</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0088-1109-47</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0088-1109-55</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020872</td>
<td class="formItem">02/25/2000</td>
<td class="formItem">02/28/2013</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALLEGRA 		
					</strong><br><span class="contentTableReg">fexofenadine hydrochloride suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0088-1097</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fexofenadine hydrochloride</strong> (fexofenadine) </td>
<td class="formItem">fexofenadine hydrochloride</td>
<td class="formItem">6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>poloxamer 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic, monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic, heptahydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xylitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0088-1097-10</td>
<td class="formItem">30 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0088-1097-20</td>
<td class="formItem">300 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021963</td>
<td class="formItem">10/16/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(783243835)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cima Labs Inc.</td>
<td class="formItem"></td>
<td class="formItem">173625823</td>
<td class="formItem">MANUFACTURE(0088-1113), ANALYSIS(0088-1113), LABEL(0088-1113), PACK(0088-1113)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S. LLC</td>
<td class="formItem"></td>
<td class="formItem">783243835</td>
<td class="formItem">MANUFACTURE(0088-1106, 0088-1107, 0088-1109, 0088-1097), ANALYSIS(0088-1106, 0088-1107, 0088-1109, 0088-1097), LABEL(0088-1106, 0088-1107, 0088-1109, 0088-1097), PACK(0088-1106, 0088-1107, 0088-1109, 0088-1097)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2892ecac-9078-460d-a940-2be297b6da59</div>
<div>Set id: 7c25b695-bbed-4ad1-aa47-de47091bc808</div>
<div>Version: 3</div>
<div>Effective Time: 20120321</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
